CD8+ T-cell-mediated immunity against malaria: A novel heterologous prime-boost strategy

Expert Review of Vaccines

Volumn 11, Issue 9, 2012, Pages 1039-1041

  Soares, Irene S ^a   Françoso, Kátia S ^a   Jampaulo, Vander O ^b   Rodrigues, Mauricio M ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CD8+ T cells; malaria vaccine; prime boost vaccination; virus like particle

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; EPITOPE; MALARIA VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; RECOMBINANT PORCINE PARVOVIRUS LIKE PARTICLE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG PURIFICATION; EFFECTOR CELL; GENE EXPRESSION; MALARIA; MEMORY CELL; NONHUMAN; PLASMODIUM YOELII; PORCINE PARVOVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPOROZOITE; VACCINATION; VIRUS LIKE AGENT;

EID: 84869451990     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.82     Document Type: Review

References (20)

1. Rodríguez D, González-Aseguinolaza G, Rodríguez JR et al. Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium. Plos One 7(4), e34445 (2012
2. Bassat Q, Alonso PL. Defying malaria: Fathoming severe Plasmodium vivax disease. Nat. Med. 17(1), 48-49 (2011
3. malERA Consultative Group on Vaccines. A research agenda for malaria eradication: Vaccines. Plos Med. 8, e1000398 (2011
4. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216(5111), 160-162 (1967
5. Epstein JE, Rao S, Williams F et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: An update. J. Infect. Dis. 196(1), 145-154 (2007
6. Rodrigues M, Nussenzweig RS, Zavala F. The relative contribution of antibodies, CD4+ and CD8+ T cells to sporozoiteinduced protection against malaria. Immunology 80(1), 1-5 (1993
7. Kumar KA, Sano G, Boscardin S et al. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444(7121), 937-940 (2006
8. Mauduit M, Grüner AC, Tewari R et al. A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites. Plos One 4(11), e7717 (2009
9. Agnandji ST, Lell B, Soulanoudjingar SS et al.; RTS,S Clinical Trials Partnership. First results of Phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365(20), 1863-1875 (2011
10. Olotu A, Lusingu J, Leach A et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anticircumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: A randomised controlled trial. Lancet Infect. Dis. 11(2), 102-109 (2011
11. Li S, Rodrigues M, Rodríguez D et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cellmediated protective immunity against malaria. Proc. Natl. Acad. Sci. USA 90(11), 5214-5218 (1993
12. Rodrigues M, Li S, Murata K et al. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J. Immunol. 153(10), 4636-4648 (1994
13. Schneider J, Gilbert SC, Blanchard TJ et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4(4), 397-402 (1998
14. McConkey SJ, Reece WH, Moorthy VS et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9(6), 729-735 (2003
15. Dunachie SJ, Walther M, Epstein JE et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun. 74(10), 5933-5942 (2006
16. Bejon P, Ogada E, Mwangi T et al. Extended follow-up following a Phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. Plos One 2(8), e707 (2007
17. Bejon P, Andrews L, Andersen RF et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. 191(4), 619-626 (2005
18. López-Macías C, Ferat-Osorio E, Tenorio-Calvo A et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 29(44), 7826-7834 (2011
19. Lori F. DermaVir: A plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS. Expert Rev. Vaccines 10(10), 1371-1384 (2011
20. Braun M, Jandus C, Maurer P et al. Virus-like particles induce robust human T-helper cell responses. Eur. J. Immunol. 42(2), 330-340 (2012